Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab maintenance dosing interval optimization in chronic plaque psoriasis
NL-OMON42493Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of secukinumab in psoriasis (4 arms), sponsored by Novartis. Started Aug 2015; status: active, not recruiting.
02
Drugs
secukinumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NL-OMON42493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42493.